Q2 EPS Estimates for Globus Medical Lifted by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Equities research analysts at Zacks Research increased their Q2 2025 earnings per share estimates for shares of Globus Medical in a note issued to investors on Tuesday, January 21st. Zacks Research analyst R. Department now expects that the medical device company will earn $0.86 per share for the quarter, up from their prior estimate of $0.85. The consensus estimate for Globus Medical’s current full-year earnings is $2.98 per share. Zacks Research also issued estimates for Globus Medical’s Q4 2025 earnings at $0.95 EPS and FY2026 earnings at $3.97 EPS.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.18. The firm had revenue of $625.71 million during the quarter, compared to analysts’ expectations of $604.69 million. Globus Medical had a return on equity of 9.98% and a net margin of 3.69%. Globus Medical’s revenue was up 63.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.57 earnings per share.

A number of other equities research analysts also recently issued reports on the stock. Royal Bank of Canada lifted their price target on shares of Globus Medical from $80.00 to $92.00 and gave the company an “outperform” rating in a research report on Wednesday, November 6th. Canaccord Genuity Group lifted their price objective on Globus Medical from $92.00 to $101.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Piper Sandler upped their target price on Globus Medical from $80.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Stifel Nicolaus raised their price target on Globus Medical from $80.00 to $92.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Finally, Wells Fargo & Company boosted their price objective on shares of Globus Medical from $88.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Globus Medical presently has a consensus rating of “Moderate Buy” and a consensus price target of $96.91.

Globus Medical Stock Up 1.7 %

Shares of NYSE GMED opened at $92.33 on Wednesday. The stock has a market capitalization of $12.57 billion, a price-to-earnings ratio of 137.80, a price-to-earnings-growth ratio of 1.73 and a beta of 1.19. Globus Medical has a 52 week low of $49.33 and a 52 week high of $92.42. The firm has a 50-day moving average price of $84.25 and a 200 day moving average price of $76.16.

Hedge Funds Weigh In On Globus Medical

A number of hedge funds have recently made changes to their positions in the stock. V Square Quantitative Management LLC purchased a new stake in shares of Globus Medical during the 3rd quarter worth about $27,000. Quarry LP lifted its position in Globus Medical by 698.4% during the third quarter. Quarry LP now owns 495 shares of the medical device company’s stock valued at $35,000 after buying an additional 433 shares in the last quarter. Farther Finance Advisors LLC grew its stake in Globus Medical by 230.5% during the third quarter. Farther Finance Advisors LLC now owns 552 shares of the medical device company’s stock worth $39,000 after buying an additional 385 shares during the period. UMB Bank n.a. increased its position in shares of Globus Medical by 60.2% in the fourth quarter. UMB Bank n.a. now owns 548 shares of the medical device company’s stock worth $45,000 after acquiring an additional 206 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Globus Medical by 40.7% in the 3rd quarter. GAMMA Investing LLC now owns 888 shares of the medical device company’s stock valued at $64,000 after acquiring an additional 257 shares during the period. Institutional investors and hedge funds own 95.16% of the company’s stock.

Insider Activity

In related news, SVP Kelly Huller sold 5,000 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $81.01, for a total transaction of $405,050.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Daniel T. Scavilla sold 60,000 shares of Globus Medical stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $80.02, for a total value of $4,801,200.00. The disclosure for this sale can be found here. Insiders sold a total of 81,667 shares of company stock valued at $6,674,554 over the last 90 days. Insiders own 18.54% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.